Heron Therapeutics, Inc.
NASDAQ:HRTXBiotechnology
+$0.01 today
- Market cap
- $51.94M
- Beta
- 1.57
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$0.16
Volume 1.81M
Average 2.90M
HRTX Total Current Assets
All assets expected to be converted to cash or used up within one year.
Heron Therapeutics, Inc.NASDAQ: HRTX
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 7.6% from a year ago
Total current assets stood at $228.98M at the end of Q1 FY2026, up 7.6% from a year earlier and down 3.8% from the prior quarter. Over 3 fiscal years it compounded at +5.0% a year.
Context
- Total current assets amounted to 93.0% of total assets at the end of Q1 FY2026, up 2.7 pp from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +7.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 238.07M USD
- Year-over-year change
- +13.9%
- 4-year CAGR
- -1.6%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 238.07M | +13.9% |
| FY2024 | 2024-12-31 | 209.01M | +10.7% |
| FY2023 | 2023-12-31 | 188.77M | -8.1% |
| FY2022 | 2022-12-31 | 205.44M | -19.3% |
| FY2021 | 2021-12-31 | 254.42M | — |
Total Current Assets vs competitors
How HRTX compares with its peers on the latest reported figures
- HRTX's Mar 2026 total current assets of $228.98M is the highest of the 10 companies compared; the peer median is $138.57M.
- Its year-over-year change of +7.6% is the 8th highest of 10, against a peer median of +21.6%.
- Total current assets amounts to 93.0% of total assets for HRTX, versus a peer median of 77.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $228.98M | +7.6% | +5.0% | 93.0% | |
| Mar 2026 | $206.04M | -33.6% | -18.5% | 77.5% | |
| Mar 2026 | $204.92M | +170.2% | -13.1% | 84.8% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $142.59M | +398.5% | +50.1% | 97.8% |
| Mar 2026 | $140M | +10.6% | +22.8% | 72.9% | |
| Sep 2026 | $138.57M | +182.5% | +61.8% | 98.2% | |
| Mar 2026 | $86.36M | +42.7% | +14.1% | 84.4% | |
| Mar 2026 | $65.13M | +21.6% | -19.4% | 22.2% | |
| Mar 2026 | $52.17M | +10.9% | +9.4% | 65.2% | |
| Mar 2026 | $1.37M | -81.4% | — | 41.2% | |
| Peer median (excluding HRTX) | $138.57M | +21.6% | +11.7% | 77.5% | |
Competitors are the stored peer set for HRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 90.54M | 15.36M | 28.68M | 25.8M | 28.65M |
| Short-term Investments | 67.04M | 69.49M | 51.73M | 33.48M | 17.98M |
| Net Receivables | 35.5M | 52.05M | 60.14M | 78.88M | 89.59M |
| Inventory | 48.38M | 54.57M | 42.11M | 53.16M | 92.75M |
| Other Current Assets | 0 | 13.96M | 6.12M | 17.69M | 9.1M |
| Total Current Assets | 254.42M | 205.44M | 188.77M | 209.01M | 238.07M |
| Property, Plant & Equipment (Net) | 33.56M | 29.81M | 25.6M | 17.65M | 12.4M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 17.72M | 15.71M | 8.13M | 6.48M | 5.41M |
| Total Non-current Assets | 51.28M | 45.52M | 33.73M | 24.13M | 17.81M |
| Total Assets | 305.71M | 250.95M | 222.51M | 233.15M | 255.88M |
| Account Payables | 3.87M | 3.59M | 3.8M | 11.71M | 8.99M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 13.48M | 11.28M | 7.85M | 7.96M | 8.61M |
| Total Current Liabilities | 71.06M | 82.36M | 79.69M | 91.46M | 96.1M |
| Long-term Debt | 149.08M | 149.28M | 173.75M | 174.73M | 140.64M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 241K | 241K | 615K | 4.81M |
| Total Non-current Liabilities | 157.08M | 155.02M | 176.79M | 175.34M | 145.45M |
| Total Liabilities | 228.14M | 237.38M | 256.48M | 266.8M | 241.54M |
| Common Stock | 1.02M | 1.19M | 1.5M | 1.52M | 1.88M |
| Retained Earnings | (1.61B) | (1.8B) | (1.91B) | (1.92B) | (1.94B) |
| Accumulated OCI | (6K) | (19K) | 13K | 13K | 4K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 77.57M | 13.57M | (33.97M) | (33.65M) | 14.33M |
| Total Debt | 159.5M | 157.48M | 179.63M | 177.76M | 140.64M |
| Net Debt | 68.95M | 142.11M | 150.95M | 151.96M | 111.99M |
Heron Therapeutics, Inc.
NASDAQ:HRTX
Intrinsic Alpha fair value
Locked
Current Price
$0.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.